Pharming Groups drug “Leniolisib, “ was approved by the US Food and Drug Administration (FDA) on Friday to treat a rare hereditary illness that causes a weakened immune system.

Leniolisib, to be marketed as Joenja, is the first medicine licensed in the United States to treat activated phosphoinositide 3-kinase delta syndrome (APDS), which is specifically an immunodeficiency that affects 1 to 2 persons in a million. Joenja is an oral medication that targets and inhibits phosphoinositide 3-kinase delta (P13K).

According to the company, Joenja will be available for shipment in mid-April and launch in the United States in early April.

People with APDS lack functioning of immune, B, and T cells, making it difficult to fight off bacterial and viral infections. It also increases the risk of long-term lung damage and lymphoma.

The FDA granted approval based on findings from a late-stage study that indicated the medicine helped normalize immunological function as evaluated by a considerable rise in immune response-generating B cells and a reduction in lymph node size.

(Source: https://health.economictimes.indiatimes.com/news/pharma/us-fda-approves-pharmings-immune-disorder-drug/98982789)